Actively Recruiting
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Led by Gruppo Italiano Malattie EMatologiche dell'Adulto · Updated on 2025-03-14
736
Participants Needed
1
Research Sites
259 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxis (antiplatelet agents, heparins, oral anticoagulants) in preventing venous thromboembolism (VTE).
CONDITIONS
Official Title
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age equal to or greater than 18 years of age
- New diagnosis of symptomatic Multiple Myeloma according to CRAB or SLIM criteria
- First active treatment for Multiple Myeloma started after recruitment in the study
- Signed informed consent
You will not qualify if you...
- Patients having had thrombosis within 6 months before diagnosis of Multiple Myeloma
- Patients needing combined antithrombotic regimens (e.g., vitamin K antagonists, direct oral anticoagulants, or low molecular weight heparin plus one or two antiplatelet drugs)
- Ongoing first active treatment for Multiple Myeloma initiated before the study start
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione Policlinico Universitario A. Gemelli IRCCS UOC Servizio e DH di Ematologia
Roma, Italy
Actively Recruiting
Research Team
P
Paola Fazi
CONTACT
E
Enrico Crea
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here